Callodine Group Appoints Winston Black as Head of Life Sciences Finance Strategy

BOSTON--(BUSINESS WIRE)--Callodine Group (“Callodine”) is pleased to announce the appointment of Winston Black as the Head of Callodine’s newly formed Life Sciences Finance Strategy. In this role, Mr. Black will lead the firm’s efforts in sourcing, underwriting, and managing structured investments across the life sciences sector, with a focus on commercial-stage companies.

Mr. Black brings more than 25 years of investment and operational experience, with deep domain expertise in life sciences finance. He has been active in the space since 2005 and has invested over $1 billion in similar strategies across the capital structure. His proven ability to navigate complex transactions and his established network of clinical, regulatory, legal, and financial professionals uniquely position him to lead the growth of Callodine’s life sciences strategy.

Prior to joining Callodine, Mr. Black was the Co-Founder, Chief Executive Officer, and Chairman of SWK Holdings (NASDAQ: SWKH), where he led the execution of a highly successful life sciences finance strategy from 2012 to 2022. Under his leadership, SWK deployed capital across a diverse portfolio of structured credit investments, royalties, and other asset-backed opportunities in the healthcare sector. Previously, Mr. Black co-founded PBS Capital Management, a boutique investment firm focused on structured and asset-based investments in life sciences. He also held senior roles at Highland Capital Management, where he managed a $2.3 billion healthcare portfolio across leveraged loans, high-yield bonds, and royalty streams.

“Winston’s experience, industry knowledge, and deep credit background make him a tremendous addition to the Callodine platform,” said James Morrow, Chief Executive Officer of Callodine. “We believe the current market presents a compelling opportunity in life sciences finance, and under Winston’s leadership, we are well-positioned to capitalize on that opportunity on behalf of our investors.”

“Driven by innovation, the life science market represents a promising investment landscape by delivering novel products and services that aim to improve patient care and reduce healthcare system costs,” said Mr. Black. “I am thrilled to join Callodine—a firm distinguished by its robust capabilities across income-producing asset classes and its commitment to specialized investment strategies. I look forward to partnering with the team to identify and finance opportunities that generate meaningful value for our investors and support progress in healthcare.”

This appointment reflects Callodine’s continued focus on offering specialized forms of private credit within the middle market.

About Callodine Group
Callodine Group is a Boston-based asset management platform with over $20 billion in assets under management across affiliated advisers. The Firm seeks to pursue predominantly income-oriented investment strategies with high cash yields that offer the potential for equity-like returns. Callodine’s specialized and dedicated investment teams target strategies across private credit, real estate credit, public equities and fixed income on behalf of institutional and individual investors.